Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E F Smit

Showing results (91-100 of 185) with videos related to

Pageof 19
Sort By:
British Journal of Cancer|October 20, 2012
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenibJ L Kuiper, J S W Lind, H J M Groen, et al.
British Journal of Cancer|August 16, 2006
Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)E C J Phernambucq, B Biesma, E F Smit, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancerC Dickhoff, M Dahele, M A Paul, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 16, 2012
Trimodality therapy for superior sulcus tumours: evolution and evaluation of a treatment protocolC G Vos, K J Hartemink, J L G Blaauwgeers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2000
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patientsG Giaccone, E F Smit, J P van Meerbeeck, et al.
Current Pharmaceutical Design|September 15, 2012
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cellsE Giovannetti, M Labots, H Dekker, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 13, 2010
Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometryR Honeywell, K Yarzadah, E Giovannetti, et al.
British Journal of Cancer|December 17, 2009
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patientsL Vroling, J S W Lind, R R de Haas, et al.
Lung Cancer (Amsterdam, Netherlands)|July 1, 2014
Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and functionC Dickhoff, K J Hartemink, P M van de Ven, et al.
Anticancer Research|June 16, 1999
A PCR-aided transcript titration assay (PATTY) to measure topoisomerase I gene expression in human tumor specimensG J Meersma, M Bakker, H J Groen, et al.
Pageof 19

Showing results (91-100 of 185) with videos related to

Sort By:
Pageof 19
British Journal of Cancer|October 20, 2012
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenibJ L Kuiper, J S W Lind, H J M Groen, et al.
British Journal of Cancer|August 16, 2006
Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)E C J Phernambucq, B Biesma, E F Smit, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancerC Dickhoff, M Dahele, M A Paul, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 16, 2012
Trimodality therapy for superior sulcus tumours: evolution and evaluation of a treatment protocolC G Vos, K J Hartemink, J L G Blaauwgeers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2000
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patientsG Giaccone, E F Smit, J P van Meerbeeck, et al.
Current Pharmaceutical Design|September 15, 2012
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cellsE Giovannetti, M Labots, H Dekker, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 13, 2010
Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometryR Honeywell, K Yarzadah, E Giovannetti, et al.
British Journal of Cancer|December 17, 2009
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patientsL Vroling, J S W Lind, R R de Haas, et al.
Lung Cancer (Amsterdam, Netherlands)|July 1, 2014
Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and functionC Dickhoff, K J Hartemink, P M van de Ven, et al.
Anticancer Research|June 16, 1999
A PCR-aided transcript titration assay (PATTY) to measure topoisomerase I gene expression in human tumor specimensG J Meersma, M Bakker, H J Groen, et al.
Pageof 19